| Literature DB >> 27736796 |
Bin Xu1,2, Lujun Chen1,2, Jing Li1,2, Xiao Zheng1,2, Liangrong Shi1,2,3, Changping Wu1,2,3, Jingting Jiang1,2.
Abstract
The detailed understanding of the immunobiology of tumor microenvironment has recently translated into new therapeutic approach against human cancers. Besides the role of immune cells mediating adaptive immune responses, the tumor infiltrating components of the innate immune system including, neutrophils, mast cells, NK cells, and macrophages, also role importantly in anti-tumor immunity. In our present study, we retrospectively analyzed the prognostic value of the densities of tumor infiltrating NK cells and macrophages in esophageal cancer tissues derived from stage II+III patients. Our results showed that the density of the infiltrating NK cells in tumor stroma was significantly associated with nodal status. In addition, the densities of the infiltrating NK cells in tumor nest, and the infiltrating macrophages in tumor nest as well as in tumor stroma, were significantly associated with patients' postoperative prognoses. Furthermore, the combination of infiltrating NK cells in tumor nest and stroma, or the combination of infiltrating macrophages in tumor nest and stroma, could also be used as important prognostic tool in predicting the survival of the stage II+III esophageal cancer patients.Entities:
Keywords: NK cells; esophageal cancer; macrophages; tumor infiltrating immune cells; tumor microenvironment
Mesh:
Substances:
Year: 2016 PMID: 27736796 PMCID: PMC5342711 DOI: 10.18632/oncotarget.12484
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Correlation between clinical parameters and the infiltrating density of CD57+ NK cells in esophageal cancer tissues
| Clinical parameters | Cases | CD57+ NK cells in Tumor Nest | CD57+ NK cells in Tumor Stroma | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Low | High | Low | High | ||||||||
| % | % | % | % | ||||||||
| Gender | |||||||||||
| Male | 102 | 33 | 32.35 | 69 | 67.65 | 0.313 | 63 | 61.76 | 39 | 38.24 | 0.717 |
| Female | 36 | 15 | 41.67 | 21 | 58.33 | 21 | 58.33 | 15 | 41.67 | ||
| Age (years) | |||||||||||
| < 60 | 73 | 23 | 31.51 | 50 | 68.49 | 0.392 | 42 | 57.53 | 31 | 42.47 | 0.395 |
| ≥ 60 | 65 | 25 | 38.46 | 40 | 61.54 | 42 | 64.62 | 23 | 35.38 | ||
| Tumor size (cm) | |||||||||||
| ≤ 3.5 | 56 | 17 | 30.36 | 39 | 69.64 | 0.367 | 35 | 62.50 | 21 | 37.50 | 0.746 |
| > 3.5 | 82 | 31 | 37.80 | 51 | 62.20 | 49 | 59.76 | 33 | 40.24 | ||
| Tumor (T) status | |||||||||||
| pT1 | 6 | 4 | 66.67 | 2 | 33.33 | 0.384 | 4 | 66.67 | 2 | 33.33 | 0.804 |
| pT2 | 65 | 22 | 33.85 | 43 | 66.15 | 37 | 56.92 | 28 | 43.08 | ||
| pT3 | 54 | 17 | 31.48 | 37 | 68.52 | 34 | 62.96 | 20 | 37.04 | ||
| pT4 | 13 | 5 | 38.46 | 8 | 61.54 | 9 | 69.23 | 4 | 30.77 | ||
| Nodal (N) status | |||||||||||
| N0 | 84 | 30 | 35.71 | 54 | 64.29 | 0.774 | 58 | 69.05 | 26 | 30.95 | |
| N1 | 54 | 18 | 33.33 | 36 | 66.67 | 26 | 48.15 | 28 | 51.85 | ||
| TNM stage | |||||||||||
| II | 101 | 35 | 34.65 | 66 | 65.35 | 0.958 | 62 | 61.39 | 39 | 38.61 | 0.837 |
| III | 37 | 13 | 35.14 | 24 | 64.86 | 22 | 59.46 | 15 | 40.54 | ||
| Total | 138 | ||||||||||
Values in bold signify P < 0.05.
Tumor status is classified as follows: pT1, invasion of lamina propria or submucosa; pT2, invasion of muscularis propria; pT3, invasion of adventitia; and pT4, invasion of adjacent structures.
Nodal status is classified as follows: N0, no regional lymph-node metastasis; N1, regional lymph-node metastasis.
Correlation between clinical parameters and the infiltrating density of CD68+ macrophages in esophageal cancer tissues
| Clinical parameters | Cases | CD68+ macrophages in Tumor Nest | CD68+ macrophages in Tumor Stroma | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Low | High | Low | High | ||||||||
| % | % | % | % | ||||||||
| Gender | |||||||||||
| Male | 102 | 50 | 49.02 | 52 | 50.98 | 0.919 | 71 | 69.61 | 31 | 30.39 | 0.540 |
| Female | 36 | 18 | 50.00 | 18 | 50.00 | 27 | 75 | 9 | 25.00 | ||
| Age (years) | |||||||||||
| < 60 | 73 | 37 | 50.68 | 36 | 49.32 | 0.726 | 22 | 30.14 | 51 | 69.86 | 0.752 |
| ≥ 60 | 65 | 31 | 47.69 | 34 | 52.31 | 18 | 27.69 | 47 | 72.31 | ||
| Tumor size (cm) | |||||||||||
| ≤ 3.5 | 56 | 30 | 53.57 | 26 | 46.43 | 0.404 | 17 | 41.46 | 39 | 95.12 | 0.769 |
| >3.5 | 82 | 38 | 46.34 | 44 | 53.66 | 23 | 23.71 | 59 | 60.82 | ||
| Tumor (T) status | |||||||||||
| pT1 | 6 | 1 | 16.67 | 5 | 83.33 | 0.900 | 1 | 16.67 | 5 | 83.33 | 0.509 |
| pT2 | 65 | 34 | 52.31 | 31 | 47.69 | 19 | 29.23 | 46 | 70.77 | ||
| pT3 | 54 | 28 | 51.85 | 26 | 48.15 | 15 | 27.78 | 39 | 72.22 | ||
| pT4 | 13 | 5 | 38.46 | 8 | 61.54 | 5 | 38.46 | 8 | 61.54 | ||
| Nodal (N) status | |||||||||||
| N0 | 84 | 46 | 54.76 | 38 | 45.24 | 0.108 | 27 | 32.14 | 57 | 67.86 | 0.308 |
| N1 | 54 | 22 | 40.74 | 32 | 59.26 | 13 | 24.07 | 41 | 75.93 | ||
| TNM stage | |||||||||||
| II | 101 | 50 | 49.50 | 51 | 50.50 | 0.929 | 29 | 28.71 | 72 | 71.29 | 0.907 |
| III | 37 | 18 | 48.65 | 19 | 51.35 | 11 | 29.73 | 26 | 70.27 | ||
| Total | 138 | ||||||||||
The same description as in Table 1.
Figure 1Immunohistochemical analysis of CD57+ NK cells and CD68+ macrophages in esophageal cancer tissues from stage II+III patients
Panel (A) depicts the high and low infiltration of CD57+ NK cells and CD68+ macrophages in tumor nests, while panel (B) depicts the high and low infiltration of CD57+ NK cells and CD68+macrophages in tumor stroma.
Figure 2Survival analysis of the infiltrating densities of CD57+ NK cells and CD68+ macrophages in esophageal cancer tissues from stage II+III patients
Patients with high infiltration density of CD57+ NK cells in tumor nest had a significantly better OS than those with low infiltrating (P = 0.0187), but there was no significant difference between high and low CD57+ NK cells infiltrating in tumor stroma (P = 0.6508). Patients with high infiltration density of CD68+ macrophages in tumor nest had a significantly worse OS than those with low infiltrating (P = 0.0332), but a higher infiltrating density of CD68+ macrophages in tumor stroma significantly correlated with a better OS (P = 0.0407). Patients with high infiltration density of CD57+ NK cells in tumor nest and low infiltration density in tumor stroma had a best OS, both high or both low infiltrating in tumor nest and stroma had a medium OS and the other patients with low infiltration density of CD57+ NK cells in tumor nest and high infiltrating density in tumor stroma had a worst OS (P = 0.0014). Patients with low infiltrating density of CD68+macrophages in tumor nest and high infiltrating density in tumor stroma had a best OS, both high infiltration in tumor nest and stroma and both low infiltration in tumor nest and stroma had the medium OS and the patients with high infiltrating density of CD68+ macrophages in tumor nest and low infiltrating density in tumor stroma had a worst OS (P = 0.0136).
Figure 3Correlation of the overall survival rate with different combinations of CD57+ NK cells and CD68+ macrophages in the tumor nests
Only patients with high infiltrating density of CD57+ NKcells and low infiltrating density of CD68+macrophages in tumor nest and the patients with low infiltrating density of CD57+ NKcells and high infiltrating density of CD68+macrophages in tumor nest were included for this survival analysis.
Cox model analysis for the correlation between the infiltrating density of CD57+ NK cells in tumor nest and hazard ratio (n = 138)
| Clinical parameters | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | |||
| Gender | ||||||
| Male/Female | 0.982 | 0.682−1.536 | 0.937 | 0.986 | 0.615−1.579 | 0.952 |
| Age (years) | ||||||
| ≥ 60/< 60 | 0.930 | 0.627−1.378 | 0.717 | 0.756 | 0.497−1.152 | 0.193 |
| Tumor size (cm) | ||||||
| ≥ 3.5/< 3.5 | 1.417 | 0.941−2.132 | 0.095 | 1.431 | 0.920−2.227 | 0.112 |
| TNM Stage | ||||||
| SIII/SII | 1.310 | 0.850−2.019 | 0.220 | 1.211 | 0.768−1.911 | 0.410 |
| Treatment | ||||||
| Chemotherapy/None | 1.132 | 0.610−2.098 | 0.695 | 0.893 | 0.464−1.718 | 0.735 |
| Radiotherapy/ None | 0.651 | 0.398−1.064 | 0.087 | 0.569 | 0.342−0.946 | |
| Both/None | 0.658 | 0.091−4.743 | 0.678 | 0.681 | 0.089−5.201 | 0.681 |
| NK cells in tumor nest | ||||||
| High/Low | 0.614 | 0.410−0.920 | 0.597 | 0.392−0.908 | ||
Values in bold signify P < 0.05.
Cox model analysis for the correlation between the infiltrating density of CD57+ NK cells in tumor stroma and hazard ratio (n = 138)
| Clinical parameters | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | |||
| Gender | ||||||
| Male/Female | 0.982 | 0.682−1.536 | 0.937 | 0.926 | 0.580−1.479 | 0.749 |
| Age (years) | ||||||
| ≥ 60/< 60 | 0.930 | 0.627−1.378 | 0.717 | 0.825 | 0.546−1.248 | 0.362 |
| Tumor size (cm) | ||||||
| ≥ 3.5/< 3.5 | 1.417 | 0.941−2.132 | 0.095 | 1.466 | 0.943−2.277 | 0.089 |
| TNM Stage | ||||||
| SIII/SII | 1.310 | 0.850−2.019 | 0.220 | 1.220 | 0.777−1.915 | 0.388 |
| Treatment | ||||||
| Chemotherapy/None | 1.132 | 0.610−2.098 | 0.695 | 0.968 | 0.506−1.851 | 0.922 |
| Radiotherapy/ None | 0.651 | 0.398−1.064 | 0.087 | 0.596 | 0.360−0.988 | |
| Both/None | 0.658 | 0.091−4.743 | 0.678 | 0.651 | 0.085−4.955 | 0.680 |
| NK cells in tumor stroma | ||||||
| High/Low | 1.096 | 0.735−1.636 | 0.653 | 1.015 | 0.670−1.536 | 0.945 |
Values in bold signify P < 0.05.
Prognostic value of the combination based on infiltrating density of CD57+ NK cells in tumor nest and in tumor stroma in Cox proportional hazards mode analysis (n = 138)
| Clinical parameters | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | |||
| Gender | ||||||
| Male/Female | 0.982 | 0.682−1.536 | 0.937 | 1.046 | 0.645−1.698 | 0.854 |
| Age (years) | ||||||
| ≥ 60/< 60 | 0.930 | 0.627−1.378 | 0.717 | 0.795 | 0.522−1.213 | 0.288 |
| Tumor size (cm) | ||||||
| ≥ 3.5/< 3.5 | 1.417 | 0.941−2.132 | 0.095 | 1.332 | 0.852−2.082 | 0.209 |
| TNM Stage | ||||||
| SIII/SII | 1.310 | 0.850−2.019 | 0.220 | 1.247 | 0.788−1.973 | 0.346 |
| Treatment | ||||||
| Chemotherapy/None | 1.132 | 0.610−2.098 | 0.695 | 0.939 | 0.486−1.812 | 0.851 |
| Radiotherapy/ None | 0.651 | 0.398−1.064 | 0.087 | 0.609 | 0.366−1.014 | 0.056 |
| Both/None | 0.658 | 0.091−4.743 | 0.678 | 0.800 | 0.103−6.227 | 0.831 |
| NK cells in tumor nest and stroma | ||||||
| Nest high and Stroma low /Nest low and Stroma high | 0.079 | 0.018−0.353 | 0.105 | 0.023−0.485 | ||
| Both low /Nest low and Stroma high | 0.160 | 0.037−0.687 | 0.211 | 0.047−0.954 | ||
| Both high /Nest low and Stroma high | 0.122 | 0.028−0.527 | 0.152 | 0.034−0.681 | ||
Values in bold signify P < 0.05.
Cox model analysis for the correlation between the infiltrating density of CD68+ macrophages in tumor nest and hazard ratio (n = 138)
| Clinical parameters | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | |||
| Gender | ||||||
| Male/Female | 0.982 | 0.682−1.536 | 0.937 | 0.912 | 0.574−1.449 | 0.697 |
| Age (years) | ||||||
| ≥ 60/< 60 | 0.930 | 0.627−1.378 | 0.717 | 0.842 | 0.559−1.269 | 0.412 |
| Tumor size (cm) | ||||||
| ≥ 3.5/< 3.5 | 1.417 | 0.941−2.132 | 0.095 | 1.466 | 0.944−2.277 | 0.089 |
| TNM Stage | ||||||
| SIII/SII | 1.310 | 0.850−2.019 | 0.220 | 1.170 | 0.744−1.839 | 0.497 |
| Treatment | ||||||
| Chemotherapy/None | 1.132 | 0.610−2.098 | 0.695 | 0.935 | 0.491−1.780 | 0.837 |
| Radiotherapy/ None | 0.651 | 0.398−1.064 | 0.087 | 0.599 | 0.363−0.987 | |
| Both/None | 0.658 | 0.091−4.743 | 0.678 | 0.823 | 0.106−6.380 | 0.852 |
| CD68+ macrophages in tumor nest | ||||||
| High/Low | 1.541 | 1.038−2.289 | 1.488 | 0.996−2.221 | 0.052 | |
Values in bold signify P < 0.05.
Cox model analysis for the correlation between the infiltrating density of CD68+ macropahges in tumor stoma and hazard ratio (n = 138)
| Clinical parameters | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | |||
| Gender | ||||||
| Male/Female | 0.982 | 0.682−1.536 | 0.937 | 0.894 | 0.563−1.420 | 0.635 |
| Age (years) | ||||||
| ≥ 60/< 60 | 0.930 | 0.627−1.378 | 0.717 | 0.802 | 0.534−1.206 | 0.289 |
| Tumor size (cm) | ||||||
| ≥ 3.5/< 3.5 | 1.417 | 0.941−2.132 | 0.095 | 1.410 | 0.908−2.192 | 0.126 |
| TNM Stage | ||||||
| SIII/SII | 1.310 | 0.850−2.019 | 0.220 | 1.222 | 0.778−1.920 | 0.384 |
| Treatment | ||||||
| Chemotherapy/None | 1.132 | 0.610−2.098 | 0.695 | 1.096 | 0.568−2.115 | 0.784 |
| Radiotherapy/ None | 0.651 | 0.398−1.064 | 0.087 | 0.544 | 0.327−0.904 | |
| Both/None | 0.658 | 0.091−4.743 | 0.678 | 0.692 | 0.090−5.290 | 0.722 |
| CD68+ macrophages in tumor stroma | ||||||
| High/Low | 0.651 | 0.429−0.990 | 0.586 | 0.378–0.908 | ||
Values in bold signify P < 0.05.
Prognostic value of the combination base on infiltrating density of CD68+ macrophages in tumor nest and in tumor stroma in COX proportional hazards mode analysis (n = 138)
| Clinical parameters | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | |||
| Gender | ||||||
| Male/Female | 0.982 | 0.682−1.536 | 0.937 | 0.869 | 0.541−1.394 | 0.560 |
| Age (years) | ||||||
| ≥ 60/< 60 | 0.930 | 0.627−1.378 | 0.717 | 0.820 | 0.545−1.232 | 0.339 |
| Tumor size (cm) | ||||||
| ≥ 3.5/< 3.5 | 1.417 | 0.941−2.132 | 0.095 | 1.405 | 0.901−2.192 | 0.134 |
| TNM Stage | ||||||
| SIII/SII | 1.310 | 0.850−2.019 | 0.220 | 1.156 | 0.733−1.822 | 0.533 |
| Treatment | ||||||
| Chemotherapy/None | 1.132 | 0.610−2.098 | 0.695 | 1.073 | 0.556−2.071 | 0.835 |
| Radiotherapy/ None | 0.651 | 0.398−1.064 | 0.087 | 0.539 | 0.325−0.893 | |
| Both/None | 0.658 | 0.091−4.743 | 0.678 | 1.021 | 0.130−8.033 | 0.984 |
| CD68+ macrophages in nest and stroma | ||||||
| Nest high and Stroma low /Nest low and Stroma high | 2.913 | 1.416−5.995 | 3.236 | 1.541−6.794 | ||
| Both low /Nest low and Stroma high | 2.006 | 1.116−3.607 | 2.221 | 1.210−4.075 | ||
| Both high /Nest low and Stroma high | 1.906 | 1.149−3.161 | 1.872 | 1.118−3.133 | ||
Values in bold signify P < 0.05.
Prognostic value of the combination based on infiltrating densities of CD57+ NK cells and CD68+ macrophages in cancer tissues in COX proportional hazards mode analysis (n = 138)
| Clinical parameters | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | |||
| Gender | ||||||
| Male/Female | 0.982 | 0.682−1.536 | 0.937 | 0.973 | 0.604−1.567 | 0.910 |
| Age (years) | ||||||
| ≥ 60/< 60 | 0.930 | 0.627−1.378 | 0.717 | 0.790 | 0.517−1.205 | 0.274 |
| Tumor size (cm) | ||||||
| ≥ 3.5/< 3.5 | 1.417 | 0.941−2.132 | 0.095 | 1.404 | 0.899−2.194 | 0.136 |
| TNM Stage | ||||||
| SIII/SII | 1.310 | 0.850−2.019 | 0.220 | 1.215 | 0.758−1.947 | 0.418 |
| Treatment | ||||||
| Chemotherapy/None | 1.132 | 0.610−2.098 | 0.695 | 0.849 | 0.440−1.638 | 0.625 |
| Radiotherapy/ None | 0.651 | 0.398−1.064 | 0.087 | 0.581 | 0.350−0.963 | |
| Both/None | 0.658 | 0.091−4.743 | 0.678 | 0.840 | 0.107−6.592 | 0.868 |
| Combined with NK cells and macrophages | ||||||
| CD57 low and CD68 high /CD57 high and CD68 low | 2.761 | 1.541−4.946 | 2.712 | 1.492−4.930 | ||
| Both low /CD57 high and CD68 low | 1.567 | 0.865−2.838 | 0.139 | 1.617 | 0.870−3.007 | 0.129 |
| Both high /CD57 high and CD68 low | 1.514 | 0.907−2.525 | 0.112 | 1.467 | 0.867−2.484 | 0.153 |
Values in bold signify P < 0.05.